| Zeng, Jun |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight |
|
|
| Not yet recruiting | 2 | 300 | RoW | MDR-001, Placebo | MindRank AI Ltd | Obesity, Overweight and Obesity | 07/25 | 09/25 | | |
| Woyach, Jennifer |
ALLIANCE A041202, NCT01886872: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 547 | Canada, US | Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima | National Cancer Institute (NCI) | Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia | 08/18 | 01/25 | | |
|
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
A041702, NCT03737981: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 454 | US | Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Observation, Inspection, Visual Inspection, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto | National Cancer Institute (NCI) | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/27 | 06/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
NCT02005289: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL |
|
|
| Active, not recruiting | 2 | 41 | US | MOR00208, anti-CD19 MAb XmAb5574, anti-CD19 MoAb XmAb5574, XmAb5574, lenalidomide, CC-5013, IMiD-1, Revlimid, Correlative Studies, laboratory biomarker analysis | Ohio State University Comprehensive Cancer Center, MorphoSys AG | Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma | 12/24 | 12/24 | | |
|
|
|
|
NCT02518555: Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Active, not recruiting | 2 | 42 | US | Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Ibrutinib, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, PCV13 Vaccine, Prevnar 13, Quality-of-Life Assessment, Quality of Life Assessment, Trivalent Influenza Vaccine, Flu prevention, Flu prophylaxis, Flu shot, Flu vaccination, Fluarix, Fluzone, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV | Jennifer Woyach, Pharmacyclics LLC. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/24 | | |
NCT05873712: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome |
|
|
| Recruiting | 2 | 24 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Lymph Node Biopsy, Biopsy of Lymph Node, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB | Aseel Alsouqi, BeiGene USA, Inc. | Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed | 12/26 | 12/26 | | |
NCT02303392: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 1 | 34 | US | Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis | Jennifer Woyach, Karyopharm Therapeutics Inc | Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | 04/22 | 12/22 | | |
NCT04439006: Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization |
|
|
| Completed | 1 | 10 | US | Best Practice, standard of care, standard therapy, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765 | Jennifer Woyach, Janssen Scientific Affairs, LLC | Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed | 09/22 | 09/22 | | |
| Active, not recruiting | 1 | 15 | US | Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study | Jennifer Woyach | Chronic Lymphocytic Leukemia | 12/24 | 12/24 | | |
| Recruiting | 1 | 52 | US, RoW | SGR-1505 | Schrödinger, Inc. | Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma | 03/26 | 03/26 | | |
| Wu, hui R |
| Completed | 4 | 310 | RoW | Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT] | Children's Hospital of Chongqing Medical University | Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen | 10/23 | 10/23 | | |
NCT06537115: Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia |
|
|
| Recruiting | 4 | 450 | RoW | exercise, whey protein powder, Eldecalcitol | Zhejiang Provincial People's Hospital | Sarcopenia | 05/26 | 05/27 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT04253873: Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas |
|
|
| Recruiting | 2 | 40 | RoW | Apatinib, temozolomide | WuHui | High-grade Gliomas | 12/21 | 12/22 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
NCT05073549: Optimizing Antibiotic Use in Neonatal Intensive Care Units in China |
|
|
| Recruiting | N/A | 10000 | RoW | Collaborative Antimicrobial Stewardship Program (ASP) | Children's Hospital of Fudan University, China Medical Board | Neonates | 09/23 | 12/23 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
| Levy, Moshe |
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation |
|
|
| Completed | 3 | 56 | US | ABL001 | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia - Chronic Phase | 06/23 | 06/24 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids |
|
|
| Recruiting | 3 | 150 | Europe, Japan, US, RoW | Ianalumab, VAY736, Eltrombopag, ETB115, Placebo | Novartis Pharmaceuticals | Primary Immune Thrombocytopenia | 08/25 | 05/28 | | |
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 3 | 225 | Europe, Japan, US, RoW | Ianalumab, VAY736, Placebo, Corticosteroids | Novartis Pharmaceuticals | Primary Immune Thrombocytopenia (ITP) | 04/26 | 12/28 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
VAYHIA, NCT05648968: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
|
|
| Recruiting | 3 | 90 | Europe, Japan, US, RoW | Ianalumab, VAY736, Placebo | Novartis Pharmaceuticals | Warm Autoimmune Hemolytic Anemia (wAIHA) | 03/26 | 02/29 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Completed | 2 | 39 | US | MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine) | Novartis Pharmaceuticals | Myelodysplastic Syndrome (MDS) | 09/23 | 09/24 | | |
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy |
|
|
| Recruiting | 2 | 76 | US, RoW | Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza | Stemline Therapeutics, Inc. | Acute Myeloid Leukemia | 02/28 | 02/30 | | |
| Active, not recruiting | 2 | 196 | US | asciminib, ABL001 | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia - Chronic Phase | 09/25 | 10/27 | | |
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Terminated | 1/2 | 27 | Canada, US | TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj | Takeda | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 08/23 | 11/23 | | |
NCT04358393: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS |
|
|
| Recruiting | 1/2 | 69 | US | APG-115, 5-azacitidine, Vidaza, Azadine | Ascentage Pharma Group Inc. | AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS | 12/24 | 12/25 | | |
SET-101, NCT05121103: A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma |
|
|
| Terminated | 1 | 13 | US | EZM0414 | Epizyme, Inc. | Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse | 04/24 | 04/24 | | |
NCT05155709 / 2021-001165-21: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. |
|
|
| Terminated | 1 | 14 | Europe, US, RoW | siremadlin, HDM201, venetoclax, azacitidine | Novartis Pharmaceuticals, Novartis Pharma AG | Acute Myeloid Leukemia | 04/24 | 04/24 | | |
| Completed | 1 | 15 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 06/24 | 06/24 | | |
| Song, Qibin |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment |
|
|
| Not yet recruiting | 2 | 40 | NA | Almonertinib, HS-10296 | Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer, EGFR Gene Mutation | 01/24 | 01/24 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
| Recruiting | 1 | 18 | RoW | HV-101 | Hervor Therapeutics, Renmin Hospital of Wuhan University | Advanced Solid Tumors | 05/25 | 03/26 | | |
| Gelatti, Ana |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
AMIGO-1, NCT05299125: Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations |
|
|
| Recruiting | 2 | 49 | RoW | Amivantamab, Lazertinib, Pemetrexed 500 mg | Latin American Cooperative Oncology Group, Janssen, LP | Metastatic Non-small Cell Lung Cancers | 10/26 | 04/28 | | |
| Completed | N/A | 101 | RoW | | Latin American Cooperative Oncology Group | Carcinoma, Non-Small-Cell Lung | 02/23 | 03/23 | | |
| Xu, Xinhua |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04367909: A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Nimotuzumab, Docetaxel, Carboplatin | Xin-Hua Xu | Oral Squamous Cell Carcinoma | 12/21 | 12/22 | | |
NCT03863483: A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy. |
|
|
| Recruiting | 2 | 70 | RoW | Sintilimab, Docetaxel, Pemetrexed, Placebo | Xin-Hua Xu | Nonsquamous Non-Small Cell Lung Cancer | 12/21 | 12/22 | | |
NCT03830411: A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy |
|
|
| Recruiting | 2 | 76 | RoW | Sintilimab, IBI308, Docetaxel, Pemetrexed | Xin-Hua Xu | Nonsquamous Non-Small Cell Lung Cancer | 06/22 | 06/22 | | |
NCT06467500: A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy |
|
|
| Recruiting | 2 | 48 | RoW | Cadonilimab (AK104) | Xin-Hua Xu | Non-small Cell Lung Cancer | 12/26 | 12/26 | | |
NCT06029829: The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. |
|
|
| Recruiting | 2 | 60 | RoW | Sintilimab | Xin-Hua Xu | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
NCT05749042: A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 70 | RoW | Sintilimab, Cisplatin, Radiotherapy | Xin-Hua Xu | Oral Cavity Squamous Cell Carcinoma | 01/25 | 01/25 | | |
| Zhang, Yongchang |
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | 3 | 12000 | RoW | Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed | Hunan Province Tumor Hospital | Lung Cancer | 07/25 | 09/27 | | |
NCT05549037: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC |
|
|
| Recruiting | 3 | 210 | RoW | Pembrolizumab, Sintilimab, time-of-day of administration of immunochemotherapy | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 2/3 | 1200 | RoW | Anlotinib plus the same Immune Checkpoint Inhibitors., Pembrolizumab, Sintilimab etc. have been used in the previous treatment., Anlotinib plus the new Immune Checkpoint Inhibitors., Pembrolizumab, Sintilimab etc. have not been used in the previous treatment., Anlotinib, Anlotinib monotherapy. | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/28 | 03/29 | | |
NCT05014464: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Crizotinib, Alectinib, Brigatinib, Lorlatinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Paclitaxel | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 06/26 | 08/27 | | |
ESSENTIAL, NCT05284539: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer |
|
|
| Recruiting | 2 | 760 | RoW | Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab, Pemetrexed, Bevacizumab, Pembrolizumab, Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 10/27 | | |
NCT04951947: JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | JS201 combine with Lenvatinib | Hunan Province Tumor Hospital | Small-cell Lung Cancer | 12/24 | 06/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC |
|
|
| Completed | 2 | 40 | RoW | Toripalimab, platinum-based chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation |
|
|
| Recruiting | 2 | 6000 | RoW | Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc. | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation | 12/26 | 12/27 | | |
| Recruiting | 2 | 43 | RoW | Anlotinib and Docetaxel | Yongchang Zhang | Non-Squamous Non Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04322578: Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC |
|
|
| Recruiting | 2 | 120 | RoW | Crizotinib, Savolitinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Bevacizumab | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/25 | 03/26 | | |
NCT05584267: Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy |
|
|
| Recruiting | 2 | 140 | RoW | radiotherapy, Chemotherapy + immunotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 11/25 | 12/26 | | |
NCT05266846: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK |
|
|
| Recruiting | 2 | 78 | RoW | Pembrolizumab injection, pemetrexed, Bevacizumab, CISPLATIN | Hunan Province Tumor Hospital | ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy | 11/26 | 02/27 | | |
| Recruiting | 2 | 71 | RoW | SHR-1701 Combined With Fluazopalil | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04144569: PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 Combined With Pyrotinib | Yongchang Zhang | HER2 Insertion Mutation Positive Advanced NSCLC | 12/24 | 12/24 | | |
EPIC, NCT06440954: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases |
|
|
| Recruiting | 2 | 220 | RoW | Intrathecal pemetrexed, pemetrexed | Hunan Province Tumor Hospital, Hunan Cancer Hospital | Non-Small Cell Lung Cancer | 12/26 | 04/27 | | |
NCT05295212: Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB |
|
|
| Recruiting | 2 | 120 | RoW | Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 12/24 | 07/25 | | |
WUKONG-32, NCT06348927: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC |
|
|
| Recruiting | 2 | 52 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/25 | 04/27 | | |
| Recruiting | 2 | 100 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/25 | 12/27 | | |
FORCE, NCT05379803: High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases |
|
|
| Recruiting | 2 | 40 | RoW | Furmonertinib, AST2818 | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 03/25 | | |
Example, NCT06604351: Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction |
|
|
| Not yet recruiting | 2 | 39 | RoW | Sintilimab, Nab-Paclitaxel, and Carboplatin | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/27 | 05/29 | | |
NCT06537297: Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases |
|
|
| Not yet recruiting | 2 | 30 | RoW | Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab, intrathecal pemetrexed, high-dose furmonertinib, bevacizumab | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 08/25 | 04/26 | | |
NCT05296603: Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 83 | RoW | IBI-322 Plus Lenvatinib | Hunan Province Tumor Hospital | Small Cell Lung Cancer | 10/24 | 12/25 | | |
NCT06634667: Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance |
|
|
| Not yet recruiting | 2 | 30 | RoW | third-generation EGFR-TKI combined with anlotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 08/26 | 04/27 | | |
NCT05296278: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC |
|
|
| Recruiting | 2 | 70 | RoW | IBI-323 combined with bevacizumab plus Platinum | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 12/25 | 04/26 | | |
NCT06706219: Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC |
|
|
| Not yet recruiting | 2 | 50 | RoW | Sacituzumab tirumotecan plus pembrolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer (Stage III) | 03/28 | 05/29 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
Helpful, NCT06521034: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 124 | RoW | FHND-9041, EGFR-TKI | Yongchang Zhang, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Sensitizing Mutation | 05/21 | 05/21 | | |
NCT06220318: Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 155 | RoW | C019199, C019199 Tablets, Sintilimab, IBI308 | Fujian Haixi Pharmaceuticals Co., Ltd. | Solid Tumor | 08/26 | 08/26 | | |
NCT06306456: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC |
|
|
| Recruiting | 1/2 | 94 | RoW | GH21, Tagrisso | Suzhou Genhouse Bio Co., Ltd. | Non-Small Cell Lung Cancer With EGFR Mutation | 12/25 | 12/26 | | |
NCT06109558: The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC |
|
|
| Recruiting | 1/2 | 120 | RoW | LMV-12(HE003), Osimertinib | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer | 12/26 | 07/27 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT04777084: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. |
|
|
| Recruiting | 1 | 120 | RoW | IBI318 | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
| Recruiting | 1 | 150 | RoW | TQB2922 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
